New drug cocktail targets rare lung cancer mutation in chinese patients

NCT ID NCT05195632

Ongoing Disease control Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 patients who have not had prior BRAF or MEK inhibitor treatment will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: encorafenib and binimetinib combination
What this could lead to: If successful, this could provide a new targeted treatment option for Chinese patients with a specific genetic mutation in advanced lung cancer, potentially shrinking tumors and delaying progression.
What could go wrong: This is a mid-stage trial with only 63 participants, so results may not apply to all patients. Side effects from the drug combination are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, China
Beijing Chest Hospital, Capital Medical University

Beijing, China
Chongqing University Cancer Hospital

Chongqing, China
First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China
Fujian Medical University Union Hospital

Fuzhou, China
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian)

Fuzhou, China
Guangdong Provincial People's Hospital

Guangzhou, China
Guangxi Medical University Affiliated Tumor Hospital

Nanning, China
Hainan General Hospital

Haikou, China
Harbin Medical University Cancer Hospital

Harbin, China
Henan Cancer Hospital

Zhengzhou, China
Liaoning Cancer Hospital & Institute

Shenyang, China
Linyi Cancer Hospital

Linyi, China
Peking University First Hospital

Beijing, China
Peking University Shenzhen Hospital

Shenzhen, China
Shandong Cancer Hospital

Jinan, China
Shanxi Provincial Cancer Hospital

Taiyuan, China
Sichuan Cancer Hospital

Chengdu, China
Sun Yat-sen University Cancer Center

Guangzhou, China
Taipei Veterans General Hospital

Taipei, Taiwan
The First Affiliated Hospital of Jinzhou Medical University

Jinzhou, China
The First Affiliated Hospital of Nanchang University

Nanchang, China
The First Hospital of China Medical University

Shenyang, China
The First Hospital of Jilin University

Changchun, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, China
The Northern Jiangsu People's Hospital

Yangzhou, China
The Second Hospital of Dalian University

Dalian, China
Tianjin Cancer Hospital Airport Hospital

Tianjin, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, China
Union Hospital Tongji medical college Huazhong University of Science and Technology

Wuhan, China
Xiangya Hospital Central South University

Changsha, China
Yantai Yuhuangding Hospital

Yantai, China
Zhejiang Cancer Hospital

Hangzhou, China
Zhejiang University School of Medicine, Sir Run Run Shaw Hospital

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.